Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.250
-0.030 (-2.34%)
May 15, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
The conference highlighted a robust pipeline in targeted radiotherapy, with lead programs advancing in AML, solid tumors, and cell/gene therapy. Promising clinical data, large market opportunities, and a strong financial position support continued growth and partnership opportunities.
-
Revitalized clinical programs are set to achieve key milestones in 2025, with Actimab-A advancing in AML and solid tumors, and a new prostate cancer therapy showing strong preclinical results. R&D investments and a solid cash position support these initiatives.